Recombinant Human Soluble Thrombomodulin is Associated with Attenuation Of sepsis-induced Renal Impairment by Inhibition of Extracellular Histone Release

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2020 Jan 24

PMID 31971961

Citations 7

Authors

Masayuki Akatsuka

Yoshiki Masuda

Hiroomi Tatsumi

Michiaki Yamakage

Affiliations

Soon will be listed here.

Abstract

Multiple organ dysfunction induced by sepsis often involves kidney injury. Extracellular histones released in response to damage-associated molecular patterns are known to facilitate sepsis-induced organ dysfunction. Recombinant human soluble thrombomodulin (rhTM) and its lectin-like domain (D1) exert anti-inflammatory effects and neutralize damage-associated molecular patterns. However, the effects of rhTM and D1 on extracellular histone H3 levels and kidney injury remain poorly understood. Our purpose was to investigate the association between extracellular histone H3 levels and kidney injury, and to clarify the effects of rhTM and D1 on extracellular histone H3 levels, kidney injury, and survival in sepsis-induced rats. Rats in whom sepsis was induced via cecal ligation and puncture were used in this study. Histone H3 levels, histopathology of the kidneys, and the survival rate of rats at 24 h after cecal ligation and puncture were investigated. Histone H3 levels increased over time following cecal ligation and puncture. Histopathological analyses indicated that the distribution of degeneration foci among tubular epithelial cells of the kidney and levels of histone H3 increased simultaneously. Administration of rhTM and D1 significantly reduced histone H3 levels compared with that in the vehicle-treated group and improved kidney injury. The survival rates of rats in rhTM- and D1-treated groups were significantly higher than that in the vehicle-treated group. The results of this study indicated that rhTM and its D1 similarly reduce elevated histone H3 levels, thereby reducing acute kidney injury. Our findings also proposed that rhTM and D1 show potential as new treatment strategies for sepsis combined with acute kidney injury.

Citing Articles

Emerging therapeutic strategies targeting extracellular histones for critical and inflammatory diseases: an updated narrative review.

Yang T, Peng J, Zhang Z, Chen Y, Liu Z, Jiang L Front Immunol. 2024; 15:1438984.

PMID: 39206200 PMC: 11349558. DOI: 10.3389/fimmu.2024.1438984.

Obeticholic acid ameliorates sepsis-induced renal mitochondrial damage by inhibiting the NF-κb signaling pathway.

Jing D, Liu J, Qin D, Lin J, Li T, Li Y Ren Fail. 2024; 46(2):2368090.

PMID: 39108162 PMC: 11308967. DOI: 10.1080/0886022X.2024.2368090.

Effects of recombinant human soluble thrombomodulin on neutrophil extracellular traps in the kidney of a mouse model of endotoxin shock.

Harada T, Shimomura Y, Nishida O, Maeda M, Kato Y, Nakamura T Fujita Med J. 2023; 9(3):225-230.

PMID: 37554943 PMC: 10405902. DOI: 10.20407/fmj.2022-026.

Combination therapy of Ulinastatin with Thrombomodulin alleviates endotoxin (LPS) - induced liver and kidney injury via inhibiting apoptosis, oxidative stress and HMGB1/TLR4/NF-κB pathway.

Zhang X, Su C, Zhao S, Li J, Yu F Bioengineered. 2022; 13(2):2951-2970.

PMID: 35148668 PMC: 8973693. DOI: 10.1080/21655979.2021.2024686.

Efferocytosis and Anthrax: Implications for Bacterial Sepsis?.

Mytych J, Pan Z, Farris A J Cell Immunol. 2021; 3(3):133-139.

PMID: 34708219 PMC: 8547791. DOI: 10.33696/immunology.3.090.

References

Allam R, Scherbaum C, Darisipudi M, Mulay S, Hagele H, Lichtnekert J . Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4. J Am Soc Nephrol. 2012; 23(8):1375-88. PMC: 3402284. DOI: 10.1681/ASN.2011111077. View

Wang H, Bloom O, Zhang M, Vishnubhakat J, Ombrellino M, Che J . HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999; 285(5425):248-51. DOI: 10.1126/science.285.5425.248. View

Yegenaga I, Hoste E, Van Biesen W, Vanholder R, Benoit D, Kantarci G . Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome: results of a prospective study. Am J Kidney Dis. 2004; 43(5):817-24. DOI: 10.1053/j.ajkd.2003.12.045. View

Nagato M, Okamoto K, Abe Y, Higure A, Yamaguchi K . Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia. Crit Care Med. 2009; 37(7):2181-6. DOI: 10.1097/CCM.0b013e3181a55184. View

Schmidt A, Yan S, Yan S, STERN D . The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001; 108(7):949-55. PMC: 200958. DOI: 10.1172/JCI14002. View

Bagshaw S, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M . Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol. 2007; 2(3):431-9. DOI: 10.2215/CJN.03681106. View

Sutton T, Fisher C, Molitoris B . Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int. 2002; 62(5):1539-49. DOI: 10.1046/j.1523-1755.2002.00631.x. View

Sunden-Cullberg J, Norrby-Teglund A, Treutiger C . The role of high mobility group box-1 protein in severe sepsis. Curr Opin Infect Dis. 2006; 19(3):231-6. DOI: 10.1097/01.qco.0000224816.96986.67. View

Silk E, Zhao H, Weng H, Ma D . The role of extracellular histone in organ injury. Cell Death Dis. 2017; 8(5):e2812. PMC: 5520745. DOI: 10.1038/cddis.2017.52. View

10.

Abeyama K, Stern D, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M . The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005; 115(5):1267-74. PMC: 1077171. DOI: 10.1172/JCI22782. View

11.

Scaffidi P, Misteli T, Bianchi M . Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002; 418(6894):191-5. DOI: 10.1038/nature00858. View

12.

Xu J, Zhang X, Pelayo R, Monestier M, Ammollo C, Semeraro F . Extracellular histones are major mediators of death in sepsis. Nat Med. 2009; 15(11):1318-21. PMC: 2783754. DOI: 10.1038/nm.2053. View

13.

Bouchard J, Acharya A, Cerda J, Maccariello E, Madarasu R, Tolwani A . A Prospective International Multicenter Study of AKI in the Intensive Care Unit. Clin J Am Soc Nephrol. 2015; 10(8):1324-31. PMC: 4527019. DOI: 10.2215/CJN.04360514. View

14.

Festing M, Altman D . Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J. 2002; 43(4):244-58. DOI: 10.1093/ilar.43.4.244. View

15.

Loghmani H, Conway E . Exploring traditional and nontraditional roles for thrombomodulin. Blood. 2018; 132(2):148-158. DOI: 10.1182/blood-2017-12-768994. View

16.

Molitoris B, Sutton T . Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney Int. 2004; 66(2):496-9. DOI: 10.1111/j.1523-1755.2004.761_5.x. View

17.

Ito T, Nakahara M, Masuda Y, Ono S, Yamada S, Ishikura H . Circulating histone H3 levels are increased in septic mice in a neutrophil-dependent manner: preclinical evaluation of a novel sandwich ELISA for histone H3. J Intensive Care. 2018; 6:79. PMC: 6260889. DOI: 10.1186/s40560-018-0348-y. View

18.

Osumi W, Jin D, Imai Y, Tashiro K, Li Z, Otsuki Y . Recombinant human soluble thrombomodulin improved lipopolysaccharide/d-galactosamine-induced acute liver failure in mice. J Pharmacol Sci. 2015; 129(4):233-9. DOI: 10.1016/j.jphs.2015.11.007. View

19.

Ito T, Maruyama I . Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost. 2011; 9 Suppl 1:168-73. DOI: 10.1111/j.1538-7836.2011.04319.x. View

20.

Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer J . Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2002; 101(7):2652-60. DOI: 10.1182/blood-2002-05-1300. View